21-Aug-2026
No press releases found.
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck
Seeking Alpha News (Wed, 19-Aug 2:38 PM ET)
Healthcare ETFs rally as Moderna nearly doubles on melanoma win
Seeking Alpha News (Wed, 19-Aug 9:13 AM ET)
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Vaneck Biotech ETF trades on the NASDAQ stock market under the symbol BBH.
As of August 21, 2026, BBH stock price climbed to $241.23 with 11,081 million shares trading.
BBH has a market cap of $476.79 million. This is considered a Small Cap stock.
In the last 3 years, BBH traded as high as $244.04 and as low as $135.34.
BBH has outperformed the market in the last year with a price return of +45.8% while the SPY ETF gained +21.7%. BBH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +31.1% and +11.4%, respectively, while the SPY returned +3.4% and -1.0%, respectively.
BBH support price is $233.42 and resistance is $240.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBH shares will trade within this expected range on the day.